UK markets open in 7 hours 32 minutes

ABIVAX Société Anonyme (AAVXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
32.50-7.20 (-18.14%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close39.70
Open32.50
Bid0.00 x 0
Ask0.00 x 0
Day's range32.50 - 32.50
52-week range21.14 - 43.97
Volume1,088
Avg. volume125
Market cap542.214M
Beta (5Y monthly)1.14
PE ratio (TTM)N/A
EPS (TTM)-2.62
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Abivax announces the release of its 2021 half-year financial report

    DGAP-News: ABIVAX / Key word(s): Half Year Report30.09.2021 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax announces the release of its 2021 half-year financial report PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publ

  • EQS Group

    Abivax late-breaking abstract presentation and Live Industry Symposium at the UEG Week Virtual 2021

    DGAP-News: ABIVAX / Key word(s): Conference28.09.2021 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax late-breaking abstract presentation and Live Industry Symposium at the UEG Week Virtual 2021Principal investigator Prof. Séverine Vermeire, M.D., Ph.D, to present Abivax's late-breaking abstract on ABX464 phase 2b study results in ulcerative colitis (UC)October 4, 2021, at 10:42-10:54 am CESTAbivax will also be hosting a Live Industry Symposium on ABX464's po

  • EQS Group

    Abivax presents first-half 2021 financial results and operations update

    DGAP-News: ABIVAX / Key word(s): Half Year Results23.09.2021 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax presents first-half 2021 financial results and operations update In May and September, Abivax reported excellent efficacy and safety results of once daily oral ABX464 in a phase 2b induction study in ulcerative colitis (UC) after 8 and 16 weeks of treatment, primary and key secondary endpoints were met Abivax also communicated additional maintenance da